Emily Fox

ID/ASP PharmD @ProvHealth🦠 | @StanfordPGY2ID, @ProvHealth, & @WVUPharmacy alum | she/her

[Dom Chan @domkchan]

And the posting is now live! Let me know if you have any questions about the ID Pharmacist/Clinical Coordinator ASP position.
https://t.co/MdYP8EksMl

#IDX #IDTwitter @TwitteRX

[Emily Fox @FoxEPharmD]

@GranulicaTESSA 👏🏼👏🏼👏🏼👏🏼so awesome 💙💛

[Emily Fox @FoxEPharmD]

@nancyclovir @AmpC_Stabler @MDAndersonNews @dont_joshme @jjjaiimee @LinK_PharmD @KelseyOlson33 These titles never disappoint 👏🏼

[Emily Fox @FoxEPharmD]

@raneempallotta Empirically our hospitals have been at 3.375 Q8 EI. Now increasing to 4.5 Q8 EI for confirmed MIC of 16. Considering increasing to 4.5 for empiric pseudomonas dosing but < 10% of our PsA isolates locally have MICs of 16 of greater

[Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 @ABsteward]

🆕️🔥 Single centre cohort study @StanfordASP @bluPharmD @DHpharmd &🌟s*
In immunocompromised pts with Invasive Mucormycosis neither upfront nor salvage antifungal combo Rx was associated with a difference in 6 week mortality compared to monotherapy
https://t.co/wx4aEnv5Ot

[Emily Fox @FoxEPharmD]

Calling all PGY1s interested in infectious diseases🚨🦠We are recruiting for our next ID PGY2 resident at @ProvOregonIDASP in Portland, OR🌲⛰️

Schedule a 30-min virtual session at the link below or meet with us at PPS for more info 👇🏼 https://t.co/PMxca6aANT

[Emily Fox @FoxEPharmD]

Calling all PGY1s interested in infectious diseases🚨🦠We are recruiting for our next ID PGY2 resident at @ProvOregonIDASP in Portland, OR🌲⛰️

Schedule a 30-min virtual session at the link below or meet with us at PPS for more info 👇🏼 https://t.co/PMxca6aANT

[Josh H @dont_joshme]

How many people are going to stop and ask about this today? 😂🤔

@nancyclovir @FoxEPharmD @OncIDPharmd @SarahSpitznogle @FTverdek @jjjaiimee

[Emily Fox @FoxEPharmD]

@mmPharmD @PharmerMeg @EricMacyMD @KimberlyBlumen1 Just came up for me today! Thankful for this thread 🙏🏻 we didn’t end up bridging

[Emily Fox @FoxEPharmD]

@PharmaSpence @ryankshields has papers describing pip-tazo regaining susceptibility following resistance development to C/T. Not sure about FDC though! https://t.co/kKuXAOmHaT We’ve seen this occur a few times at MDA, imi-rel may be worth testing?

[Emily Fox @FoxEPharmD]

@RalphTayyarMD @DHpharmd @Stanford_Med_ID Woohoo!! Go David! 💯

[Nick Stornelli @n_stornelliRX]

Pursuing ID PGY2 in phase 2 of the @ASHPOfficial match?!? Check us out! 🦠

We still have a spot available @CRMHRxResidency & will be in Phase 2 of the Match!

Check out our program: https://t.co/IXPBaUDuDx

DM if there are any questions!
#IDTwitter #RxTwitter

[Bryan White @bryan_p_white]

The @OURxResidency PGY-2 ID pharmacy residency will be going into phase 2 of the match. Want to train at an AMC with a variety of experiences including OPAT and transplantID? Please share. https://t.co/W4bfVvPN6h

[Kayla Stover @stoverkr]

Want to do an ASHP-accredited ID residency at an academic medical center and didn’t match (or participate) in Phase I? @UMMCPharmacy has a PGY2 ID spot that will be participating in Phase II. We’d love to have your application! Contact me with questions. https://t.co/5Kp4fR5hge

[Bug Pharmacist 💊🧫 Tim Gauthier @IDstewardship]

📣 The @BaptistHealthSF @BHAcademics ID PGY2 pharmacy residency will be going to phase 2 of the match.

🙏 Please pass the word along to potential candidates looking for a robust training experience

https://t.co/2zlilBD41a #MatchDay #PharmacyResidency #TwitteRx #IDtwitter

[WikiGuidelines @Wiki_Guidelines]

Seeking contributors for a new #WikiGuideline project – Care of Patients Who Inject Drugs (#PWID). Come be part of our team and help improve the care of these marginalized patients. Sign up here by 4/1/23: https://t.co/ibZXjf3eGV
@NNolanMD @rachelpbaden
#SUD #PWUD #Addiction

[Emily Fox @FoxEPharmD]

@TarynEubank @Evan_Steere @SageGreenlee @MeganHardwick1 @tydrake5 👏🏼👏🏼👏🏼👏🏼 you love to see it

[Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 @ABsteward]

A 🆕️⚡️Small retrospective single study in immunocompromised patients
Poor clinical outcomes of Piperacillin/tazobactam Vs cefepime or carbapenems for
AmpC-producing organisms
MERINO 2 no definitive answer!
Meta/Dr. Lee? No difference
An RCT ? #IDTwitter https://t.co/L0OjPDyAyN